Posts tagged: line
Medbox, Inc. Announces New Product Line for 2012
HOLLYWOOD, Calif., Jan. 26, 2012 /- Medbox, Inc. (Pinksheets: MDBX) ( www.medboxinc.com ) announced today their new lineup of products for 2012. Through their subsidiary, Prescription Vending Machines, Inc., the company sells medicine dispensing and storage systems, which are designed to be used in hospitals, pharmacies, urgent care ...
ChromaDex® Expands National Launch of its BluScience⢠Line of Dietary Supplements Through McKesson
IRVINE, Calif., Jan. 25, 2012 /- ChromaDex Corporation (OTCBB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries announced today that its BluScience ( www.bluscience.com ) line of dietary supplements is now being distributed ...
Workplace empowerment for front-line health workers creates higher job satisfaction
Frontline health workersincluding nursing assistants, paramedics and pharmacy technicianswho received a combination of benefits and support from their employers had higher job satisfaction, a new study found.
Neurotechnology announces new line of embedded biometric technologies
Neurotechnology, a provider of high-precision biometric identification technologies, today announced their new line of embedded biometric technologies, including VeriFinger Embedded SDK for fingerprint biometrics, VeriLook Embedded SDK for face biometrics and MegaMatcher Embedded SDK for multi-biometric systems using face and fingerprints in combination.
Hospitals may be treating patients as part of “production line” with early discharges requiring readmissions: Report
After figures revealed that hundreds of thousands of people every year are being sent home before they are well enough, hospitals have been accused by ministers of treating patients “like parts on a production line.”
Genzyme Reports Top-line Results For TENERE Study Of Oral Teriflunomide In Relapsing Multiple Sclerosis
Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme reported top-line results from TENERE, a Phase III clinical trial comparing the effectiveness, safety and tolerability of once-daily oral teriflunomide to interferon beta-1a (Rebif®), an approved injectable therapy, in people with relapsing forms of multiple sclerosis (RMS). The TENERE trial, ...
Nab-Paclitaxel Beats Docetaxel As First-Line Treatment For Metastatic Breast Cancer
Nab-paclitaxel (Abraxane for Injectable Suspension), at a dose of 150 mg/m2 weekly, improves overall survival (OS) to a much greater degree than conventional taxane monotherapy in women with previously untreated metastatic breast cancer (MBC), according to results of a phase II study released at the 34th Annual San Antonio Breast ...
Preliminary top-line results from XenoPort’s XP21279 Phase 2 trial for advanced Parkinson’s disease
XenoPort, Inc. announced today preliminary top-line results of a Phase 2, randomized, crossover clinical trial that compared optimized treatment with either Sinemet (immediate-release levodopa/carbidopa) or XP21279 co-formulated with carbidopa (279/CD) in advanced Parkinson's disease patients with motor fluctuations.
Oxford closes $5M revolving line of credit with Mason Health
Oxford Finance LLC, a specialty finance firm that provides senior debt to life sciences and healthcare services companies, today announced that it closed a $5 million revolving line of credit with Mason Health. Proceeds of the loan are being used to refinance existing debt and to support the operation of ...
Unigene Announces Positive Top-Line Results Of Phase 2 Oral PTH Study For The Treatment Of Osteoporosis In Postmenopausal Women
Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced positive top-line results of its Phase 2 clinical study evaluating an experimental oral parathyroid hormone (PTH) analog for the treatment of osteoporosis in 93 postmenopausal women. The study achieved its ...
Top-line results from AstraZeneca and Targacept’s TC-5214 Phase 3 studies on MDD
AstraZeneca and Targacept, Inc. today announced top-line results from the first of four RENAISSANCE Phase 3 studies investigating the efficacy and tolerability of TC-5214 as an adjunct therapy to an antidepressant in patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant treatment.